Stock AnalizAxogen, Inc. AXGN
Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026
Axogen, Inc. (AXGN) is a healthcare company listed in the US with a market value of about $3.3B. In the twelve months to September 30, 2026 it had revenue of $267M and net income of -$32M, a net margin of -12.0%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 151.6, 5-year revenue growth of 15% a year, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 88% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $267M | $225M | $187M | $159M | $139M | $127M | $112M | $107M | $84M | $60M | $41M |
| Net income | -$32M | -$16M | -$10M | -$22M | -$29M | -$27M | -$24M | -$29M | -$22M | -$10M | -$14M |
| Free cash flow | $22M | -$3M | $1M | -$20M | -$36M | -$41M | -$32M | -$25M | -$24M | -$10M | -$12M |
| EPS (diluted) | $-0.65 | $-0.34 | $-0.23 | $-0.51 | $-0.69 | $-0.65 | $-0.60 | $-0.74 | $-0.60 | $-0.00 | $-0.00 |
| Net margin | -12.0% | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | -21.2% | -27.3% | -26.7% | -17.3% | -35.1% |
| ROIC | — | -3.2% | -1.5% | -10.3% | -13.9% | -11.2% | -10.3% | -18.1% | -11.0% | -13.7% | -18.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $59.27, 6% above the current price; targets range from $56.00 to $65.00; the consensus rating is “Strong buy”; expected EPS is $0.55 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Axogen stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 88% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Axogen pay a dividend?
Not currently.
Is Axogen a good stock to buy?
We do not give buy or sell advice. Axogen scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.